Key Points The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. 10 stocks we like better than Bio-Rad Laboratories › Healthcare diagnostics product supplier Bio-Rad Laboratories (NYSE: BIO) notched twin beats in its just-released third quarter, but that wasn't enough for a choosy stock market. Investors sold out of the company's shares in the wake of that earnings report to leave it with ...

Key Takeaways Bio-Rad reported Q3 adjusted EPS of $2.26, missing estimates but rising 11.9% year over year.BIO's revenues grew 0.5% to $653 million, surpassing expectations on Life Science and Diagnostics sales.BIO's gross margin contracted 219 bps, while operating profit rose 1.2% and operating margin hit 10%.Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.74%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $1.93 per share when it actually produced earnings of $2.61, delivering a surprise of +35. ...

Bio-Rad Laboratories (NYSE:BIO) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Speaker2Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Laboratories Third Quarter 2025 Results Conference Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a questi ...

Bio-Rad Laboratories, Inc. Third Quarter 2025 Financial Results October 29, 2025 2 Q3 2025 GAAP Financial Results Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management's goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements general ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________to __________ Commission file number 001-07928 BIO-RAD LABORATORIES, INC. FORM 10-Q SEPTEMBER 30, 2025 TABLE OF CONTENTS | Part | I | – | Fi ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2025 Financial Results HERCULES, Calif.—October 29, 2025 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated ...

CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe 2025, being held November 3–5, 2025, in Vienna, Austria. The Company’s presentation will take place on Tuesday, November 4, at 3:00 p.m. CET in Presenting Company Theater 1 at the Vienna Congress and Conventio ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 ETF (MDY) and HFRX Equity Hedge Index, respectively. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its third-quarter 2025 i ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Bio-Rad Laboratories (BIO) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 29, might help the stock move higher if these key numbers are better th ...